Our innovation technologies optimize your drug discovery programs to make them faster and more reliable
For more than 25 years, Oncodesign has been investing in precision medicine research technologies, which are essential from the very first stages of the Drug Discovery process. Our technology modules allow a continuum from molecule to patient, with the goal of discovering new treatments for patients with no therapeutic options.
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.